Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults at 27 September of this month. Migraine is a disabling, neurological disease characterized by recurrent episodes of severe headache accompanied by other symptoms including nausea, vomiting, ...